The prognostic impact of multiparameter flow cytometry immunophenotyping and cytogenetic aberrancies in patients with multiple myeloma

References

• Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351(18):1860–73. doi: 10.1056/NEJMra041875
   PubMed Web of Science ®Google Scholar
• Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics. CA Cancer J Clin. 2005;55:10–30. doi: 10.3322/canjclin.55.1.10
   PubMed Web of Science ®Google Scholar
• San Miguel JF, Gutierrez NC, Mateo G, Orfao A. Conventional diagnostics in multiple myeloma. Eur J Cancer 2006;42(11):1510–9. doi: 10.1016/j.ejca.2005.11.039
   PubMed Web of Science ®Google Scholar
• Rawstron AC, Davies FE, Das Gupta R, Ashcroft AJ, Patmore R, Drayson MT, et al. Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood 2002:100(9):3095–100. doi: 10.1182/blood-2001-12-0297
   PubMed Web of Science ®Google Scholar
• Perez-Andres M, Almeida J, Martin-Ayuso M, Moro MJ, Martín-Nuñez G, Galende J, et al. Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment. Leukemia 2005;19(3):449–55. doi: 10.1038/sj.leu.2403647
   PubMed Web of Science ®Google Scholar
• Harada H, Kawano MM, Huang N, Harada Y, Iwato K, Tanabe O, et al. Phenotypic difference of normal plasma cells from mature myeloma cells. Blood 1993;81(10):2658–63.
   PubMed Web of Science ®Google Scholar
• Rawstron AC, Orfao A, Beksac M, Bezdickova L, Brooimans RA, Bumbea H, et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica 2008;93(3):431–8. doi: 10.3324/haematol.11080
   PubMed Web of Science ®Google Scholar
• Paiva B, Vidriales MB, Pérez JJ, Mateo G, Montalbán MA, Mateos MV, et al. Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients. Haematologica 2009;94(11):1599–602. doi: 10.3324/haematol.2009.009100
   PubMed Web of Science ®Google Scholar
• Mateo G, Montalbán MA, Vidriales MB, Lahuerta JJ, Mateos MV, Gutiérrez N, et al. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol. 2008;26(16):2737–44. doi: 10.1200/JCO.2007.15.4120
   PubMed Web of Science ®Google Scholar
• Moreau P, Robillard N, Avet-Loiseau H, Pineau D, Morineau N, Milpied N, et al. Patients with CD45 negative multiple myeloma receiving high-dose therapy have it shorter survival than those with CD45 positive multiple myeloma. Haematologica 2004;89(5):547–51.
   PubMed Web of Science ®Google Scholar
• Eisterer W, Bechter O, Hilbe W, van Driel M, Lokhorst HM, Thaler J, et al. CD44 Isoforms are differentially regulated in plasma cell dyscrasias and CD44v9 represents a new independent prognostic parameter in multiple myeloma. Leuk Res. 2001;25(12):1051–7. doi: 10.1016/S0145-2126(01)00075-3
   PubMed Web of Science ®Google Scholar
• Pellat-Deceunynck C, Barille S, Jego G, Puthier D, Robillard N, Pineau D, et al. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia 1998;12(12):1977–82. doi: 10.1038/sj.leu.2401211
   PubMed Web of Science ®Google Scholar
• Bahlis NJ, King AM, Kolonias D, Carlson LM, Liu HY, Hussein MA, et al. CD28-mediated Regulation of multiple myeloma cell proliferation and survival. Blood 2007;109(11):5002–1.0 doi: 10.1182/blood-2006-03-012542
   PubMed Web of Science ®Google Scholar
• Caltagirone S, Ruggeri M, Aschero S, Gilestro M2, Oddolo D2, Gay F, et al. Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies. Haematologica 2014;99(10):1611–7. doi: 10.3324/haematol.2014.103853
   PubMed Web of Science ®Google Scholar
• Kyle RA, Child JA, Anderson KC, Barlogie B, Bataille R, Bensinger W, et al. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749–57. doi: 10.1046/j.1365-2141.2003.04355.x
   PubMed Web of Science ®Google Scholar
• Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correla-tion of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36(3):842–54. doi: 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U
   PubMed Web of Science ®Google Scholar
• Hayat A, O'Brien D, O'Rourke P, McGuckin S, Fitzgerald T, Conneally E, et al. CD38 Expression level and pattern of expression remains a reliable and robust marker of progressive disease in chronic lymphocytic leukemia. Leuk Lymphoma 2006;47(11):2371–9. doi: 10.1080/10428190600947727
   PubMed Web of Science ®Google Scholar
• Nadav L, Katz BZ, Baron S, Yossipov L, Polliack A, Deutsch V, et al. Diverse niches within multiple myeloma bone marrow aspirates affect plasma cell enumeration. Br J Haematol. 2006;133(5):530–2. doi: 10.1111/j.1365-2141.2006.06068.x
   PubMed Web of Science ®Google Scholar
• Miettinen M, Lasota J. KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol. 2005;13(3):205–20. doi: 10.1097/01.pai.0000173054.83414.22
   PubMedGoogle Scholar
• Bataille R, Jego G, Robillard N, Barillé-Nion S, Harousseau JL, Moreau P, et al. The phenotype of normal, reactive and malignant plasma cells: Identification of “many and multiple myelomas” and of new targets for myeloma therapy. Haematologica 2006;91(9):1234–40.
   PubMed Web of Science ®Google Scholar
• Rudd CE, Janssen O, Cai YC, da Silva AJ, Raab M, Prasad KV. Two-step TCR zeta/CD3-CD4 and CD28 signaling in T cells: SH2/SH3 domains, protein-tyrosine and lipid kinases. Immunol Today 1994;15(5):225–34. doi: 10.1016/0167-5699(94)90248-8
   PubMedGoogle Scholar
• Robillard N, Jego G, Pellat-Deceunynck C, Pineau D, Puthier D, Mellerin MP, et al. CD28, A marker associated with tumoral expansion in multiple myeloma. Clin Cancer Res. 1998;4(6):1521–6.
   PubMed Web of Science ®Google Scholar
• Zhang XG, Gaillard JP, Robillard N, Lu ZY, Gu ZJ, Jourdan M, et al. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood 1994;83(12):3654–63.
   PubMed Web of Science ®Google Scholar
• Qiu YH, Sun ZW, Shi Q, Su CH, Chen YJ, Shi YJ, et al. Apoptosis of multiple myeloma cells induced by agonist monoclonal antibody against human CD28. Cell Immunol. 2005;236(1–2):154–60. doi: 10.1016/j.cellimm.2005.08.022
   PubMed Web of Science ®Google Scholar
• Shapiro VS, Mollenauer MN, Weiss A. Endogenous CD28 expressed on myeloma cells upregulates interleukin-8 production: implications for multiple myeloma progression. Blood 2001;98(1):187–93. doi: 10.1182/blood.V98.1.187
   PubMed Web of Science ®Google Scholar
• Wielenga VJ, Smits R, Korinek V, Smit L, Kielman M, Fodde R, et al. Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am J Pathol. 1999;154(2):515–23. doi: 10.1016/S0002-9440(10)65297-2
   PubMed Web of Science ®Google Scholar
• Ponta H, Sherman L, Herrlich PA. CD44: From adhesion molecules to signalling regulators. Nature Reviews 2003;4(1):33–45. doi: 10.1038/nrm1004
   Web of Science ®Google Scholar
• Bjorklund CC, Baladandayuthapani V, Lin HY, Jones RJ1, Kuiatse I1, Wang H, et al. Evidence of a Role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications. Leukemia 2014;28(2):373–83. doi: 10.1038/leu.2013.174
   PubMed Web of Science ®Google Scholar
• Shah N, Cabanillas F, McIntyre B, Feng L, McLaughlin P, Rodriguez MA, et al. Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomas. Leuk Lymphoma. 2012;53(1):50–6. doi: 10.3109/10428194.2011.616611
   PubMed Web of Science ®Google Scholar
• Krause DS, Spitzer TR, Stowell CP. The concentration of CD44 is increased in hematopoietic stem cell grafts of patients with acute myeloid leukemia, plasma cell myeloma, and non-Hodgkin lymphoma. Arch Pathol Lab Med. 2010;134(7):1033–8.
   PubMed Web of Science ®Google Scholar
• Dahl IM, Turesson I, Holmberg E, Lilja K. Serum hyaluronan in patients with multiple myeloma: correlation with survival and Ig concentration. Blood 1999;93(12):4144–8.
   PubMed Web of Science ®Google Scholar
• Kumar S, Rajkumar SV, Kimlinger T, Greipp PR, Witzig TE. CD45 Expression by bone marrow plasma cells in multiple myeloma: Clinical and biological correlations. Leukemia 2005;19(8):1466–70. doi: 10.1038/sj.leu.2403823
   PubMed Web of Science ®Google Scholar
• Robillard N, Pellat-Deceunynck C, Bataille R. Phenotypic characterization of the human myeloma cell growth fraction. Blood 2005;105(12):4845–8. doi: 10.1182/blood-2004-12-4700
   PubMed Web of Science ®Google Scholar
• Ocqueteau M, Orfao A, García-Sanz R, Almeida J, Gonzalez M, San Miguel JF. Expression of the CD117 antigen (c-Kit) on normal and myelomatous plasma cells. Br J Haematol. 1996;95(3):489–93. doi: 10.1111/j.1365-2141.1996.tb08993.x
   PubMed Web of Science ®Google Scholar